News | June 03, 2022
LEO Pharma strengthens its commercial organization
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
New logo reflects Thyrocare’s transformation since 1996 to its current leading position at the cutting edge of Diagnostic services
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
The product will be launched by NATCO's commercial partner Viatris.
Subscribe To Our Newsletter & Stay Updated
